Royalty Report: Medical, Supply, Wound Care – Collection: 3747


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Medical
  • Supply
  • Wound Care
  • Surgical
  • Tissue
  • Chemicals
  • Coating
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3747

License Grant
The Licensor desires to grant Licensee, an exclusive perpetual worldwide License to the Licensed Technology, the nordihydroguaratic acid and/or polymer-enhanced collagen processes, compositions and products and/or other biocompatible materials and devices to manufacture, have manufactured, market, use, offer to sell and sell, Licensed Products.
License Property
Licensed Technology means, individually and collectively, all existing patent applications and patents (6,565,960 and 6,821,530) associated with technology related to nordihydroguaratic acid (NDGA) coatings, devices, scaffolds, substrates, or other materials and/or polymer treated collagen material for medical devices, implants, prosthesis and/or constructs and methods for making same.
Field of Use
The Company is a development stage company that acquired a License for the use, adoption and development of certain core technologies developed by the University Research Foundation. This technology focuses on biomaterials for soft tissue repair, such as tendons, ligaments and cartilage, as well as other biomaterial-based products for numerous other medical applications.

IPSCIO Record ID: 1232

License Grant
The Company entered into a new License Agreement with the Licensors. The Company's exclusive license to use the technology was expanded to include the wound care field, the abdominal and thoracic (general surgery) field, and the breast field. Also in connection with the aforementioned new License Agreement, three other people received cash payments. Two of these individuals are founders of the Company; one of them is also a member of the Board of Directors and the other is an officer of the Company.
License Property
The Licensor of the Company's patented stabilization and sterilization technologies, is a shareholder of the Company, has a member of its management as a member of the Company's Board of Directors, earns a royalty on the Company's net sales of products derived from the licensed technology, and also receives a monthly consulting fee.  The Company holds rights to patented technologies for the stabilization (crosslinking) and sterilization of biological tissue which has enabled development of acellular collagen biomaterials suitable for use as wound dressings as well as for human implantation as ligament, tendon, and soft tissue repair/reinforcement patches or grafts.
Field of Use
The rights granted relate to use the technology was expanded to include the wound care field, the abdominal and thoracic (general surgery) field, and the breast field.

IPSCIO Record ID: 5290

License Grant
The Licensee entered into a five-year license agreement with Licensor relative to a technology known as OPLA. The Licensee and Licensor are committed to research and development of specified uses of the OPLA technology.
License Property
The Open-cell Polylactic Acid or OPLA is a porous polymer foam technology, and to our biomaterials technology platform in the orthopedics drug and delivery markets.  This porous tissue matrix technology facilitates wound healing in both bone and soft tissue and is bio absorbable at controlled rates for specific functions and tissues.  This technology adds a series of products, development programs and intellectual property related to porous biodegradable regeneration matrices.  Specifically, we are researching applications for articular cartilage regeneration, bone growth scaffolds for spinal and trauma applications and for the delivery of drugs and growth factors.

IPSCIO Record ID: 283919

License Grant
The Agreement provides the Company a license to patent rights and other intellectual property related to New Zealand Licensor's products and technologies for use in certain indications.  This License provides for the exclusive supply of ovine rumen and manufacture of Licensee OviTex and OviTex PRS products.
License Property
Licensors Product consist of but not limited to Ovine rumen, the forestomach of a sheep.  It is the source of the biologic material used in our products. In manufacturing our products, Licensee uses biologic material from ovine rumen because of its plentiful supply, optimal biomechanical profile and open collagen architecture that allows for rapid cellular infiltration.

Through this License, Licensee intellectual property broadly covers the development of extracellular matrix scaffolds derived from ovine rumen and methods for isolating these scaffolds from ovine rumen.

OviTex Reinforced Tissue Matrix, or OviTex, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials. OviTex PRS, addresses unmet needs in plastic and reconstructive surgery.

OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.

Field of Use
OviTex Reinforced BioScaffolds (RBSs) are intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome.

Licensee is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Licensee offer a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Licensee products are an innovative solution that integrate multiple layers of minimally-processed biologic material with interwoven polymers in a unique embroidered pattern, which we refer to as a reinforced tissue matrix.

IPSCIO Record ID: 1670

License Grant
Israeli University has assigned to the Company its worldwide rights to patents, patent applications and know-how to develop, manufacture and market products relating to biomedical polymers technology; preventing or reducing post-operative surgical adhesions; dated June 14, 1991, as amended in February 1994, as of January 1996 and as of October 1996; proprietary bioresorbable polymer technology.
License Property
The Company's bioresorbable polymer technology is based on a proprietary group of polymers.  The Company believes that these polymers display desirable properties, which enable them to be tailored to a wide variety of applications.  These properties include bioresorbability, flexibility, strength and biocompatibility.
Field of Use
Potential applications for products derived from these polymers are in medical areas such as the prevention of post-operative adhesions, sutures, stents, implantable device coatings and drug delivery.

IPSCIO Record ID: 266751

License Grant
Licensor, non-profit health care organization, grants the worldwide right and exclusive license, with the right to grant sublicenses, under the Patent Rights to make, have made, use, lease, sell, offer for sale and import for use or resale the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field.

Licensor also grants a non-exclusive license to Know-how, and a non-exclusive license to use Biological Materials in connection with licensees research and development of Licensed Products.

License Property
The patents include Reconstruction of Urological Structures with Polymeric Matrices;  Achievement of Excretory Renal Function Using a Neo-Morphogenic System In Vivo; Penile Reconstruction; Ex vivo Engineered Stents for Urethral Structures; Creation of Tissue Engineered Female Productive Organs (Vagina); Augmentation of Organ Function;  and, Tissue Engineered Uterus and Fallopian Tubes.

Biological Materials shall mean the specific proprietary biological materials, including Progeny and Unmodified Derivatives of those materials.  Progeny shall mean an unmodified descendant from the material, such as a virus from virus, cell from a cell, or organism from an organism; Unmodified Derivatives shall mean substances created by the Licensee which constitute an unmodified functional subunit or product expressed by the original material, such as subclones of unmodified cell lines, purified or fractionated subsets of the original material, proteins expressed by DNA/RNA, or monoclonal antibodies secreted by a hybridoma cell line; and Modifications shall mean substances created by the Licensee which contain or incorporate the material.

Field of Use
Field of Use shall mean the development and commercialization of tissue engineered products for human and animal therapeutics in the subfields of genitourinary, vascular tissue, nervous tissue, trachea and other subfields when and if mutually agreed upon by the parties in writing.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.